The FDA granted IND approval to begin enrolling a Phase 2 clinical trial of Sn-117m DTPA for the treatment of prostate cancer-related bone metastases. The clinical trial will begin enrolling patients soon at the University of Kentucky under the direction of primary investigator Dr Zin Myint. This study is supported by the National Cancer Institute.
